The stage of fibrosis was determined using the METAVIR scoring system
According to the METAVIR scoring system
, liver fibrosis was classified into five stages: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis.
Fibro-SURE (LabCorp), for example, uses a peripheral venous blood sample and combines the patient's age, gender, and 6 biochemical markers to generate a range of scores that correspond to the fibrosis component of the well-known METAVIR scoring system
and correlate with results of liver biopsies.
Some studies have used the Metavir scoring system
to classify liver fibrosis.
Liver stiffness was considered as the median of all valid measurements and fibrosis staging was converted to the METAVIR scoring system
as proposed by Castera et al.
The pathological diagnosis of each sample was determined based on the METAVIR scoring system
, and the fibrosis was classified into 5 stages: F0, no fibrosis; F1, expansion of portal zones; F2, expansion of most portal zones and occasional bridging; F3, expansion of most portal zones and marked bridging and occasional modules; and F4, cirrhosis.
Histological analysis results according to METAVIR scoring system
revealed that 15 (8.0%) patients were F0, 63 (35.0%) were F1, 50 (28.0%) were F2, 45 (25.0%) were F3, and 9 (5.0%) were F4.
The patients were divided into two groups according to the stage of hepatic fibrosis using the METAVIR scoring system
The Fibroscan (Echosense, Paris) was used for the measurement of liver stiffness and METAVIR scoring system
was used for calculating liver stiffness measurement (LSM) values ranging from 3.5-75 kilopascals (kpa) with normal liver stiffness value 5.5 kpa and LS value 7.1 kpa was considered for exclusion of fibrosis.
Liver biopsies were analyzed for the fibrosis stage in each center by the local pathologist, using the METAVIR scoring system
. On the same day as the biopsy specimens were obtained, biochemical parameters were collected to assess several noninvasive markers in a subgroup of 235 patients.
The Metavir scoring system
is a histological assessment of the degree of inflammatory activity and the stage of fibrosis.
Re-examination of the liver biopsy classified the specimen as F1A2 according to the METAVIR scoring system
. The patient received conventional interferon for six months until October 1996 and was considered a non-responder.